{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T13:02:44Z","timestamp":1794747764615,"version":"4.9.1"},"reference-count":177,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82060119"],"award-info":[{"award-number":["No. 82060119"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02559-5","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:25:47Z","timestamp":1772796347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Targeting HSP90 in cancer: advances in the development of inhibitors, mechanisms of action, and therapeutic applications"],"prefix":"10.1186","volume":"25","author":[{"given":"Xueyi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqing","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"2559_CR1","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1146\/annurev-biochem-060815-014124","volume":"85","author":"A Finka","year":"2016","unstructured":"Finka A, Mattoo RU, Goloubinoff P. Experimental milestones in the discovery of molecular chaperones as polypeptide unfolding enzymes. Annu Rev Biochem. 2016;85:715\u201342. https:\/\/doi.org\/10.1146\/annurev-biochem-060815-014124.","journal-title":"Annu Rev Biochem"},{"issue":"5","key":"2559_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ccell.2019.10.003","volume":"36","author":"AM Joshua","year":"2019","unstructured":"Joshua AM, Tannock IF. Companion diagnostics to identify biomarkers of response to anticancer drugs targeting the proteome. Cancer Cell. 2019;36(5):464\u20135. https:\/\/doi.org\/10.1016\/j.ccell.2019.10.003.","journal-title":"Cancer Cell"},{"key":"2559_CR3","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a034116","author":"T Taldone","year":"2020","unstructured":"Taldone T, Wang T, Rodina A, Pillarsetty NVK, Digwal CS, Sharma S, et al. A chemical biology approach to the chaperome in cancer-HSP90 and beyond. Cold Spring Harb Perspect Biol. 2020. https:\/\/doi.org\/10.1101\/cshperspect.a034116.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"10","key":"2559_CR4","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1158\/1535-7163.Mct-21-0215","volume":"20","author":"L Liu","year":"2021","unstructured":"Liu L, Deng Y, Zheng Z, Deng Z, Zhang J, Li J, et al. Hsp90 inhibitor STA9090 sensitizes hepatocellular carcinoma to hyperthermia-induced DNA damage by suppressing DNA-PKcs protein stability and mRNA transcription. Mol Cancer Ther. 2021;20(10):1880\u201392. https:\/\/doi.org\/10.1158\/1535-7163.Mct-21-0215.","journal-title":"Mol Cancer Ther"},{"key":"2559_CR5","doi-asserted-by":"publisher","unstructured":"Chagaleti BK, Baby K, Pena-Corona SI, Leyva-Gomez G, S MS, Naveen NR et al. Anti-cancer properties of Sansalvamide A, its derivatives, and analogs: an updated review. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(10):7337\u2009\u2013\u200951. https:\/\/doi.org\/10.1007\/s00210-024-03129-0.","DOI":"10.1007\/s00210-024-03129-0"},{"key":"2559_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-025-11160-3","author":"A Singh","year":"2025","unstructured":"Singh A, Maity S, Devi P, Rai A, Asati V. Recent progress and structural insights of potential Hsp90 inhibitors as anticancer agents. Mol Divers. 2025. https:\/\/doi.org\/10.1007\/s11030-025-11160-3.","journal-title":"Mol Divers"},{"issue":"1","key":"2559_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1517\/14712598.2.1.3","volume":"2","author":"A Maloney","year":"2002","unstructured":"Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther. 2002;2(1):3\u201324. https:\/\/doi.org\/10.1517\/14712598.2.1.3.","journal-title":"Expert Opin Biol Ther"},{"issue":"19","key":"2559_CR8","doi-asserted-by":"publisher","first-page":"5178","DOI":"10.1158\/1078-0432.CCR-19-3704","volume":"26","author":"MPS Dunphy","year":"2020","unstructured":"Dunphy MPS, Pressl C, Pillarsetty N, Grkovski M, Modi S, Jhaveri K, et al. First-in-Human trial of Epichaperome-Targeted PET in patients with cancer. Clin Cancer Res. 2020;26(19):5178\u201387. 10.1158\/1078\u2009\u2013\u20090432.Ccr-19-3704.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2559_CR9","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.7150\/jca.69710","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang X, Zhang J, Han Z, Ma L, Li Y. (18)F-labeled dimer-sansalvamide A cyclodecapeptide: a novel diagnostic probe to discriminate pancreatic cancer from inflammation in a nude mice model. J Cancer. 2022;13(6):1848\u201358. https:\/\/doi.org\/10.7150\/jca.69710.","journal-title":"J Cancer"},{"key":"2559_CR10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1146\/annurev-micro-032421-035644","volume":"75","author":"S Wickner","year":"2021","unstructured":"Wickner S, Nguyen TL, Genest O. The bacterial Hsp90 chaperone: cellular functions and mechanism of action. Annu Rev Microbiol. 2021;75:719\u201339. https:\/\/doi.org\/10.1146\/annurev-micro-032421-035644.","journal-title":"Annu Rev Microbiol"},{"issue":"1\u20133","key":"2559_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/s0014-5793(04)00229-7","volume":"562","author":"AS Sreedhar","year":"2004","unstructured":"Sreedhar AS, Kalm\u00e1r E, Csermely P, Shen YF. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett. 2004;562(1\u20133):11\u20135. https:\/\/doi.org\/10.1016\/s0014-5793(04)00229-7.","journal-title":"FEBS Lett"},{"key":"2559_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910317","author":"B Birbo","year":"2021","unstructured":"Birbo B, Madu EE, Madu CO, Jain A, Lu Y. Role of HSP90 in cancer. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms221910317.","journal-title":"Int J Mol Sci"},{"issue":"47","key":"2559_CR13","doi-asserted-by":"publisher","first-page":"44905","DOI":"10.1074\/jbc.M208457200","volume":"277","author":"K Richter","year":"2002","unstructured":"Richter K, Reinstein J, Buchner J. N-terminal residues regulate the catalytic efficiency of the Hsp90 ATPase cycle. J Biol Chem. 2002;277(47):44905\u201310. https:\/\/doi.org\/10.1074\/jbc.M208457200.","journal-title":"J Biol Chem"},{"issue":"2","key":"2559_CR14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/molbev\/msaa211","volume":"38","author":"PA Cote-Hammarlof","year":"2021","unstructured":"Cote-Hammarlof PA, Fragata I, Flynn J, Mavor D, Zeldovich KB, Bank C, et al. The adaptive potential of the middle domain of yeast Hsp90. Mol Biol Evol. 2021;38(2):368\u201379. https:\/\/doi.org\/10.1093\/molbev\/msaa211.","journal-title":"Mol Biol Evol"},{"key":"2559_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19092560","author":"A Hoter","year":"2018","unstructured":"Hoter A, El-Sabban ME, Naim HY. The HSP90 family: structure, regulation, function, and implications in health and disease. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19092560.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2559_CR16","first-page":"157","volume":"4","author":"JM Eckl","year":"2013","unstructured":"Eckl JM, Richter K. Functions of the Hsp90 chaperone system: lifting client proteins to new heights. Int J Biochem Mol Biol. 2013;4(4):157\u201365.","journal-title":"Int J Biochem Mol Biol"},{"issue":"6","key":"2559_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrm.2017.20","volume":"18","author":"FH Schopf","year":"2017","unstructured":"Schopf FH, Biebl MM, Buchner J. The HSP90 chaperone machinery. Nat Rev Mol Cell Biol. 2017;18(6):345\u201360. https:\/\/doi.org\/10.1038\/nrm.2017.20.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"2559_CR18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nsmb.3380","volume":"24","author":"J Oroz","year":"2017","unstructured":"Oroz J, Kim JH, Chang BJ, Zweckstetter M. Mechanistic basis for the recognition of a misfolded protein by the molecular chaperone Hsp90. Nat Struct Mol Biol. 2017;24(4):407\u201313. https:\/\/doi.org\/10.1038\/nsmb.3380.","journal-title":"Nat Struct Mol Biol"},{"issue":"12","key":"2559_CR19","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.4161\/cc.3.12.1277","volume":"3","author":"F Burrows","year":"2004","unstructured":"Burrows F, Zhang H, Kamal A. Hsp90 activation and cell cycle regulation. Cell Cycle. 2004;3(12):1530\u20136. https:\/\/doi.org\/10.4161\/cc.3.12.1277.","journal-title":"Cell Cycle"},{"issue":"16","key":"2559_CR20","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1182\/blood-2013-01-479972","volume":"122","author":"U Nayar","year":"2013","unstructured":"Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, et al. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood. 2013;122(16):2837\u201347. https:\/\/doi.org\/10.1182\/blood-2013-01-479972.","journal-title":"Blood"},{"issue":"3","key":"2559_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.celrep.2016.12.056","volume":"18","author":"I Masgras","year":"2017","unstructured":"Masgras I, Ciscato F, Brunati AM, Tibaldi E, Indraccolo S, Curtarello M, et al. Absence of neurofibromin induces an oncogenic metabolic switch via mitochondrial ERK-mediated phosphorylation of the chaperone TRAP1. Cell Rep. 2017;18(3):659\u201372. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.056.","journal-title":"Cell Rep"},{"key":"2559_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114918","volume":"164","author":"S Saber","year":"2023","unstructured":"Saber S, Hasan AM, Mohammed OA, Saleh LA, Hashish AA, Alamri MMS, et al. Ganetespib (STA-9090) augments sorafenib efficacy via necroptosis induction in hepatocellular carcinoma: implications from preclinical data for a novel therapeutic approach. Biomed Pharmacother. 2023;164:114918. https:\/\/doi.org\/10.1016\/j.biopha.2023.114918.","journal-title":"Biomed Pharmacother"},{"key":"2559_CR23","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.13737","volume":"10","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Ji S, Li X, Feng Q. Active ingredients and molecular targets of Taraxacum mongolicum against hepatocellular carcinoma: network pharmacology, molecular docking, and molecular dynamics simulation analysis. PeerJ. 2022;10:e13737. https:\/\/doi.org\/10.7717\/peerj.13737.","journal-title":"PeerJ"},{"issue":"7","key":"2559_CR24","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.celrep.2017.10.074","volume":"21","author":"N Dushukyan","year":"2017","unstructured":"Dushukyan N, Dunn DM, Sager RA, Woodford MR, Loiselle DR, Daneshvar M, et al. Phosphorylation and ubiquitination regulate protein phosphatase 5 activity and its prosurvival role in kidney cancer. Cell Rep. 2017;21(7):1883\u201395. https:\/\/doi.org\/10.1016\/j.celrep.2017.10.074.","journal-title":"Cell Rep"},{"key":"2559_CR25","doi-asserted-by":"publisher","unstructured":"Lauinger M, Christen D, Klar RFU, Roubaty C, Heilig CE, Stumpe M et al. BRAF(Deltabeta3-alphaC) in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability. Sci Adv. 2023;9(35):eade7486. https:\/\/doi.org\/10.1126\/sciadv.ade7486.","DOI":"10.1126\/sciadv.ade7486"},{"issue":"4","key":"2559_CR26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1084\/jem.20141157","volume":"212","author":"SP Methot","year":"2015","unstructured":"Methot SP, Litzler LC, Trajtenberg F, Zahn A, Robert F, Pelletier J, et al. Consecutive interactions with HSP90 and eEF1A underlie a functional maturation and storage pathway of AID in the cytoplasm. J Exp Med. 2015;212(4):581\u201396. https:\/\/doi.org\/10.1084\/jem.20141157.","journal-title":"J Exp Med"},{"issue":"1","key":"2559_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.508","volume":"5","author":"R Schulz","year":"2014","unstructured":"Schulz R, Streller F, Scheel AH, R\u00fcschoff J, Reinert MC, Dobbelstein M, et al. HER2\/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer. Cell Death Dis. 2014;5(1):e980. https:\/\/doi.org\/10.1038\/cddis.2013.508.","journal-title":"Cell Death Dis"},{"issue":"3","key":"2559_CR28","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.celrep.2016.06.043","volume":"16","author":"TN Beck","year":"2016","unstructured":"Beck TN, Korobeynikov VA, Kudinov AE, Georgopoulos R, Solanki NR, Andrews-Hoke M, et al. Anti-M\u00fcllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer. Cell Rep. 2016;16(3):657\u201371. https:\/\/doi.org\/10.1016\/j.celrep.2016.06.043.","journal-title":"Cell Rep"},{"key":"2559_CR29","doi-asserted-by":"publisher","unstructured":"Jiang X, Lin J, Shangguan C, Wang X, Xiang B, Chen J et al. Intrinsic RIG-I restrains STAT5 activation to modulate antitumor activity of CD8\u2009+\u2009T cells. J Clin Invest. 2023;133(9).\u00a0https:\/\/doi.org\/10.1172\/jci160790.","DOI":"10.1172\/jci160790"},{"issue":"1","key":"2559_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nm.4247","volume":"23","author":"S G\u00f6llner","year":"2017","unstructured":"G\u00f6llner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, et al. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nat Med. 2017;23(1):69\u201378. https:\/\/doi.org\/10.1038\/nm.4247.","journal-title":"Nat Med."},{"issue":"11","key":"2559_CR31","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1016\/j.celrep.2019.11.032","volume":"29","author":"L Gong","year":"2019","unstructured":"Gong L, Zhang Q, Pan X, Chen S, Yang L, Liu B, et al. p53 protects cells from death at the heatstroke threshold temperature. Cell Rep. 2019;29(11):3693-707.e5. https:\/\/doi.org\/10.1016\/j.celrep.2019.11.032.","journal-title":"Cell Rep."},{"issue":"35","key":"2559_CR32","doi-asserted-by":"publisher","first-page":"13106","DOI":"10.1074\/jbc.RA119.008649","volume":"294","author":"M Saline","year":"2019","unstructured":"Saline M, Badertscher L, Wolter M, Lau R, Gunnarsson A, Jacso T, et al. AMPK and AKT protein kinases hierarchically phosphorylate the N-terminus of the FOXO1 transcription factor, modulating interactions with 14-3-3 proteins. J Biol Chem. 2019;294(35):13106\u201316. https:\/\/doi.org\/10.1074\/jbc.RA119.008649.","journal-title":"J Biol Chem"},{"issue":"4","key":"2559_CR33","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.celrep.2015.12.084","volume":"14","author":"MR Woodford","year":"2016","unstructured":"Woodford MR, Truman AW, Dunn DM, Jensen SM, Cotran R, Bullard R, et al. Mps1 mediated phosphorylation of Hsp90 confers renal cell carcinoma sensitivity and selectivity to Hsp90 inhibitors. Cell Rep. 2016;14(4):872\u201384. https:\/\/doi.org\/10.1016\/j.celrep.2015.12.084.","journal-title":"Cell Rep"},{"issue":"24","key":"2559_CR34","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1038\/s41388-021-01841-2","volume":"40","author":"P Saraon","year":"2021","unstructured":"Saraon P, Pathmanathan S, Snider J, Lyakisheva A, Wong V, Stagljar I. Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches. Oncogene. 2021;40(24):4079\u201393. https:\/\/doi.org\/10.1038\/s41388-021-01841-2.","journal-title":"Oncogene"},{"issue":"8","key":"2559_CR35","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1593\/neo.12986","volume":"14","author":"A Ahsan","year":"2012","unstructured":"Ahsan A, Ramanand SG, Whitehead C, Hiniker SM, Rehemtulla A, Pratt WB, et al. Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. Neoplasia. 2012;14(8):670\u20137. https:\/\/doi.org\/10.1593\/neo.12986.","journal-title":"Neoplasia."},{"key":"2559_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7886","volume":"6","author":"V Stagni","year":"2015","unstructured":"Stagni V, Manni I, Oropallo V, Mottolese M, Di Benedetto A, Piaggio G, et al. ATM kinase sustains HER2 tumorigenicity in breast cancer. Nat Commun. 2015;6:6886. https:\/\/doi.org\/10.1038\/ncomms7886.","journal-title":"Nat Commun"},{"issue":"42","key":"2559_CR37","doi-asserted-by":"publisher","first-page":"39858","DOI":"10.1074\/jbc.M206322200","volume":"277","author":"AD Basso","year":"2002","unstructured":"Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem. 2002;277(42):39858\u201366. https:\/\/doi.org\/10.1074\/jbc.M206322200.","journal-title":"J Biol Chem"},{"issue":"10","key":"2559_CR38","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.celrep.2015.10.073","volume":"13","author":"H Zong","year":"2015","unstructured":"Zong H, Gozman A, Caldas-Lopes E, Taldone T, Sturgill E, Brennan S, et al. A hyperactive signalosome in acute myeloid leukemia drives addiction to a tumor-specific Hsp90 species. Cell Rep. 2015;13(10):2159\u201373. https:\/\/doi.org\/10.1016\/j.celrep.2015.10.073.","journal-title":"Cell Rep"},{"issue":"12","key":"2559_CR39","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1172\/jci80714","volume":"125","author":"RL Goldstein","year":"2015","unstructured":"Goldstein RL, Yang SN, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, et al. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. J Clin Invest. 2015;125(12):4559\u201371. https:\/\/doi.org\/10.1172\/jci80714.","journal-title":"J Clin Invest"},{"issue":"1","key":"2559_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.dld.2022.04.009","volume":"55","author":"Y Guo","year":"2023","unstructured":"Guo Y, Liu B, Huang T, Qi X, Li S. HOTAIR modulates hepatocellular carcinoma progression by activating FUT8\/core-fucosylated Hsp90\/MUC1\/STAT3 feedback loop via JAK1\/STAT3 cascade. Dig Liver Dis. 2023;55(1):113\u201322. https:\/\/doi.org\/10.1016\/j.dld.2022.04.009.","journal-title":"Dig Liver Dis"},{"key":"2559_CR41","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/842091","volume":"2015","author":"YZ Zhen","year":"2015","unstructured":"Zhen YZ, Lin YJ, Li KJ, Yang XS, Zhao YF, Wei J, et al. Gambogic acid lysinate induces apoptosis in breast cancer mcf-7 cells by increasing reactive oxygen species. Evid Based Complement Alternat Med. 2015;2015:842091. https:\/\/doi.org\/10.1155\/2015\/842091.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"17","key":"2559_CR42","doi-asserted-by":"publisher","first-page":"28063","DOI":"10.18632\/oncotarget.14188","volume":"8","author":"T Han","year":"2017","unstructured":"Han T, Guo M, Zhang T, Gan M, Xie C, Wang JB. A novel glutaminase inhibitor-968 inhibits the migration and proliferation of non-small cell lung cancer cells by targeting EGFR\/ERK signaling pathway. Oncotarget. 2017;8(17):28063\u201373. https:\/\/doi.org\/10.18632\/oncotarget.14188.","journal-title":"Oncotarget"},{"key":"2559_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2024.108929","volume":"136","author":"F Li","year":"2024","unstructured":"Li F, Fan Y, Zhou L, Martin DR, Liu Z, Li Z. Synthesis and characterization of (64)Cu-labeled geldanamycin derivative for imaging HSP90 expression in breast cancer. Nucl Med Biol. 2024;136:108929. https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108929.","journal-title":"Nucl Med Biol"},{"key":"2559_CR44","doi-asserted-by":"publisher","unstructured":"Ye XY, Luo QQ, Xu YH, Tang NW, Niu XM, Li ZM et al. 17-AAG suppresses growth and invasion of lung adenocarcinoma cells via regulation of the LATS1\/YAP pathway. J Cell Mol Med. 2015;19(3):651\u2009\u2013\u200963.\u00a0https:\/\/doi.org\/10.1111\/jcmm.12469.","DOI":"10.1111\/jcmm.12469"},{"key":"2559_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.103850","volume":"78","author":"S Zeynali-Moghaddam","year":"2022","unstructured":"Zeynali-Moghaddam S, Kheradmand F, Gholizadeh-Ghaleh Aziz S, Abroon S. Combination effects of capecitabine, irinotecan and 17-AAG on colorectal cancer cell line (HT-29). Ann Med Surg (Lond). 2022;78:103850. https:\/\/doi.org\/10.1016\/j.amsu.2022.103850.","journal-title":"Ann Med Surg (Lond)"},{"issue":"3","key":"2559_CR46","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.cell.2020.03.031","volume":"181","author":"M Zhang","year":"2020","unstructured":"Zhang M, Liu L, Lin X, Wang Y, Li Y, Guo Q, et al. A translocation pathway for vesicle-mediated unconventional protein secretion. Cell. 2020;181(3):637-52.e15. https:\/\/doi.org\/10.1016\/j.cell.2020.03.031.","journal-title":"Cell."},{"issue":"5","key":"2559_CR47","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/s41591-024-02957-0","volume":"30","author":"LC Cerchietti","year":"2024","unstructured":"Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, et al. Author correction: a purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med. 2024;30(5):1503. https:\/\/doi.org\/10.1038\/s41591-024-02957-0.","journal-title":"Nat Med"},{"issue":"1","key":"2559_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71157-w","volume":"10","author":"MM Anwar","year":"2020","unstructured":"Anwar MM, Shalaby M, Embaby AM, Saeed H, Agwa MM, Hussein A. Prodigiosin\/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights. Sci Rep. 2020;10(1):14706. https:\/\/doi.org\/10.1038\/s41598-020-71157-w.","journal-title":"Sci Rep"},{"issue":"3","key":"2559_CR49","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3892\/ijmm.2013.1594","volume":"33","author":"T Segawa","year":"2014","unstructured":"Segawa T, Fujii Y, Tanaka A, Bando S, Okayasu R, Ohnishi K, et al. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71. Int J Mol Med. 2014;33(3):559\u201364. https:\/\/doi.org\/10.3892\/ijmm.2013.1594.","journal-title":"Int J Mol Med"},{"key":"2559_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1454829","volume":"15","author":"AM Abdelhamid","year":"2024","unstructured":"Abdelhamid AM, Saber S, Hamad RS, Abdel-Reheim MA, Ellethy AT, Amer MM, et al. STA-9090 in combination with a statin exerts enhanced protective effects in rats fed a high-fat diet and exposed to diethylnitrosamine and thioacetamide. Front Pharmacol. 2024;15:1454829. https:\/\/doi.org\/10.3389\/fphar.2024.1454829.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2559_CR51","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.canlet.2011.07.031","volume":"312","author":"AK Samadi","year":"2011","unstructured":"Samadi AK, Zhang X, Mukerji R, Donnelly AC, Blagg BS, Cohen MS. A novel C-terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells. Cancer Lett. 2011;312(2):158\u201367. https:\/\/doi.org\/10.1016\/j.canlet.2011.07.031.","journal-title":"Cancer Lett"},{"issue":"3","key":"2559_CR52","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/cmr.0000000000000734","volume":"31","author":"JN Sanchez","year":"2021","unstructured":"Sanchez JN, Subramanian C, Chanda M, Shanguan G, Zhang N, Wang T, et al. A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas. Melanoma Res. 2021;31(3):197\u2013207. https:\/\/doi.org\/10.1097\/cmr.0000000000000734.","journal-title":"Melanoma Res"},{"issue":"22","key":"2559_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2019.126676","volume":"29","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Banerjee M, Davis RE, Blagg BSJ. Mitochondrial-targeted Hsp90 C-terminal inhibitors manifest anti-proliferative activity. Bioorg Med Chem Lett. 2019;29(22):126676. https:\/\/doi.org\/10.1016\/j.bmcl.2019.126676.","journal-title":"Bioorg Med Chem Lett"},{"issue":"24","key":"2559_CR54","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1002\/cmdc.201700630","volume":"12","author":"KM Byrd","year":"2017","unstructured":"Byrd KM, Kent CN, Blagg BSJ. Synthesis and biological evaluation of stilbene analogues as Hsp90 C-terminal inhibitors. ChemMedChem. 2017;12(24):2022\u20139. https:\/\/doi.org\/10.1002\/cmdc.201700630.","journal-title":"ChemMedChem"},{"issue":"2","key":"2559_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111039","volume":"40","author":"SJ Backe","year":"2022","unstructured":"Backe SJ, Sager RA, Regan BR, Sit J, Major LA, Bratslavsky G, et al. A specialized Hsp90 co-chaperone network regulates steroid hormone receptor response to ligand. Cell Rep. 2022;40(2):111039. https:\/\/doi.org\/10.1016\/j.celrep.2022.111039.","journal-title":"Cell Rep"},{"issue":"22","key":"2559_CR56","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1042\/bj20040690_eoc","volume":"478","author":"T Zeke","year":"2021","unstructured":"Zeke T, Morrice N, V\u00e1zquez-Martin C, Cohen PTW. Human protein phosphatase 5 dissociates from heat-shock proteins and is proteolytically activated in response to arachidonic acid and the microtubule-depolymerizing drug nocodazole. Biochem J. 2021;478(22):4025. https:\/\/doi.org\/10.1042\/bj20040690_eoc.","journal-title":"Biochem J"},{"issue":"7893","key":"2559_CR57","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-021-04236-1","volume":"601","author":"CM Noddings","year":"2022","unstructured":"Noddings CM, Wang RY, Johnson JL, Agard DA. Structure of Hsp90-p23-GR reveals the Hsp90 client-remodelling mechanism. Nature. 2022;601(7893):465\u20139. https:\/\/doi.org\/10.1038\/s41586-021-04236-1.","journal-title":"Nature"},{"issue":"3","key":"2559_CR58","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nm.3776","volume":"21","author":"M Riebold","year":"2015","unstructured":"Riebold M, Kozany C, Freiburger L, Sattler M, Buchfelder M, Hausch F, et al. A c-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease. Nat Med. 2015;21(3):276\u201380. https:\/\/doi.org\/10.1038\/nm.3776.","journal-title":"Nat Med"},{"key":"2559_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2022.129111","volume":"80","author":"E Amatya","year":"2023","unstructured":"Amatya E, Blagg BSJ. Recent advances toward the development of Hsp90 c-terminal inhibitors. Bioorg Med Chem Lett. 2023;80:129111. https:\/\/doi.org\/10.1016\/j.bmcl.2022.129111.","journal-title":"Bioorg Med Chem Lett"},{"issue":"10","key":"2559_CR60","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.chembiol.2021.03.016","volume":"28","author":"L Li","year":"2021","unstructured":"Li L, Chen N, Xia D, Xu S, Dai W, Tong Y, et al. Discovery of a covalent inhibitor of heat shock protein 90 with antitumor activity that blocks the co-chaperone binding via C-terminal modification. Cell Chem Biol. 2021;28(10):1446-59.e6. https:\/\/doi.org\/10.1016\/j.chembiol.2021.03.016.","journal-title":"Cell Chem Biol."},{"issue":"1","key":"2559_CR61","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2019.08.020","volume":"179","author":"VA Lopez","year":"2019","unstructured":"Lopez VA, Park BC, Nowak D, Sreelatha A, Zembek P, Fernandez J, et al. A bacterial effector mimics a host HSP90 client to undermine immunity. Cell. 2019;179(1):205-18.e21. https:\/\/doi.org\/10.1016\/j.cell.2019.08.020.","journal-title":"Cell."},{"key":"2559_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/ph15111341","author":"G Tassone","year":"2022","unstructured":"Tassone G, Mazzorana M, Pozzi C. Structural basis of parasitic HSP90 ATPase inhibition by small molecules. Pharmaceuticals (Basel). 2022. https:\/\/doi.org\/10.3390\/ph15111341.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"2559_CR63","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax2277","volume":"5","author":"L Wang","year":"2019","unstructured":"Wang L, Zhang L, Li L, Jiang J, Zheng Z, Shang J, et al. Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer. Sci Adv. 2019;5(9):eaax2277. https:\/\/doi.org\/10.1126\/sciadv.aax2277.","journal-title":"Sci Adv"},{"key":"2559_CR64","doi-asserted-by":"publisher","unstructured":"Lerner Y, Sukumaran S, Chua MS, So SK, Qvit N. Exploring biomolecular interaction between the molecular chaperone Hsp90 and its client protein kinase Cdc37 using field-effect biosensing technology. J Vis Exp. 2022(181).\u00a0https:\/\/doi.org\/10.3791\/63495.","DOI":"10.3791\/63495"},{"issue":"10","key":"2559_CR65","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.tibs.2017.07.002","volume":"42","author":"KA Verba","year":"2017","unstructured":"Verba KA, Agard DA. How Hsp90 and Cdc37 lubricate kinase molecular switches. Trends Biochem Sci. 2017;42(10):799\u2013811. https:\/\/doi.org\/10.1016\/j.tibs.2017.07.002.","journal-title":"Trends Biochem Sci"},{"issue":"4","key":"2559_CR66","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/s41401-021-00737-x","volume":"43","author":"CJ Cheng","year":"2022","unstructured":"Cheng CJ, Liu KX, Zhang M, Shen FK, Ye LL, Wu WB, et al. Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity. Acta Pharmacol Sin. 2022;43(4):1046\u201358. https:\/\/doi.org\/10.1038\/s41401-021-00737-x.","journal-title":"Acta Pharmacol Sin."},{"issue":"39","key":"2559_CR67","doi-asserted-by":"publisher","first-page":"28347","DOI":"10.1039\/d4ra05878j","volume":"14","author":"J Dernovsek","year":"2024","unstructured":"Dernovsek J, Gradisek N, Zajec Z, Urbancic D, Cingl J, Gorican T, et al. Discovery of new Hsp90-Cdc37 protein-protein interaction inhibitors: in silico screening and optimization of anticancer activity. RSC Adv. 2024;14(39):28347\u201375. https:\/\/doi.org\/10.1039\/d4ra05878j.","journal-title":"RSC Adv."},{"issue":"21","key":"2559_CR68","doi-asserted-by":"publisher","first-page":"5431","DOI":"10.1016\/j.bmc.2016.08.070","volume":"24","author":"F Jiang","year":"2016","unstructured":"Jiang F, Wang HJ, Bao QC, Wang L, Jin YH, Zhang Q, et al. Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties. Bioorg Med Chem. 2016;24(21):5431\u20139. https:\/\/doi.org\/10.1016\/j.bmc.2016.08.070.","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"2559_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202413618","volume":"64","author":"L Zhang","year":"2025","unstructured":"Zhang L, Liu W, Zheng Z, Zhang Q, He Y, Gu J, et al. Allosteric CDC37 inhibitor disrupts chaperone complex to block CDK4\/6 maturation. Angew Chem Int Ed Engl. 2025;64(2):e202413618. https:\/\/doi.org\/10.1002\/anie.202413618.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"23","key":"2559_CR70","doi-asserted-by":"publisher","first-page":"10798","DOI":"10.1021\/acs.jmedchem.9b01290","volume":"62","author":"N Li","year":"2019","unstructured":"Li N, Xu M, Wang B, Shi Z, Zhao Z, Tang Y, et al. Discovery of novel celastrol derivatives as Hsp90-Cdc37 interaction disruptors with antitumor activity. J Med Chem. 2019;62(23):10798\u2013815. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01290.","journal-title":"J Med Chem"},{"issue":"11","key":"2559_CR71","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/1873-3468.14080","volume":"595","author":"JP Muller","year":"2021","unstructured":"Muller JP, Klempnauer KH. The CDC37-HSP90 chaperone complex co-translationally degrades the nascent kinase-dead mutant of HIPK2. FEBS Lett. 2021;595(11):1559\u201368. https:\/\/doi.org\/10.1002\/1873-3468.14080.","journal-title":"FEBS Lett"},{"issue":"1","key":"2559_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0602-8","volume":"11","author":"T Li","year":"2018","unstructured":"Li T, Jiang HL, Tong YG, Lu JJ. Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery. J Hematol Oncol. 2018;11(1):59. https:\/\/doi.org\/10.1186\/s13045-018-0602-8.","journal-title":"J Hematol Oncol"},{"key":"2559_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108396","volume":"245","author":"J Dernovsek","year":"2023","unstructured":"Dernovsek J, Tomasic T. Following the design path of isoform-selective Hsp90 inhibitors: small differences, great opportunities. Pharmacol Ther. 2023;245:108396. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108396.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"2559_CR74","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1021\/acs.jmedchem.0c01700","volume":"64","author":"SJ Mishra","year":"2021","unstructured":"Mishra SJ, Liu W, Beebe K, Banerjee M, Kent CN, Munthali V, et al. The development of Hsp90\u03b2-selective inhibitors to overcome detriments associated with pan-Hsp90 inhibition. J Med Chem. 2021;64(3):1545\u201357. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01700.","journal-title":"J Med Chem"},{"issue":"19","key":"2559_CR75","doi-asserted-by":"publisher","first-page":"10547","DOI":"10.1002\/anie.202015422","volume":"60","author":"SJ Mishra","year":"2021","unstructured":"Mishra SJ, Khandelwal A, Banerjee M, Balch M, Peng S, Davis RE, et al. Selective inhibition of the Hsp90alpha Isoform. Angew Chem Int Ed Engl. 2021;60(19):10547\u201351. https:\/\/doi.org\/10.1002\/anie.202015422.","journal-title":"Angew Chem Int Ed Engl."},{"key":"2559_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117925","volume":"297","author":"MA Serwetnyk","year":"2025","unstructured":"Serwetnyk MA, Strunden T, Mersich I, Barlow D, D\u2019Amico T, Mishra SJ, et al. Optimization of an Hsp90\u03b2-selective inhibitor via exploration of the Hsp90\u00a0N-terminal ATP-binding pocket. Eur J Med Chem. 2025;297:117925. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117925.","journal-title":"Eur J Med Chem"},{"key":"2559_CR77","doi-asserted-by":"publisher","unstructured":"Khandelwal A, Kent CN, Balch M, Peng S, Mishra SJ, Deng J et al. Structure-guided design of an Hsp90beta N-terminal isoform-selective inhibitor. Nat Commun. 2018;9(1):425.\u00a0https:\/\/doi.org\/10.1038\/s41467-017-02013-1.","DOI":"10.1038\/s41467-017-02013-1"},{"issue":"7","key":"2559_CR78","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1021\/acs.jmedchem.6b00085","volume":"59","author":"VM Crowley","year":"2016","unstructured":"Crowley VM, Khandelwal A, Mishra S, Stothert AR, Huard DJ, Zhao J, et al. Development of glucose regulated protein 94-selective inhibitors based on the BnIm and radamide scaffold. J Med Chem. 2016;59(7):3471\u201388. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00085.","journal-title":"J Med Chem"},{"key":"2559_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115531","volume":"258","author":"T Merfeld","year":"2023","unstructured":"Merfeld T, Peng S, Keegan BM, Crowley VM, Brackett CM, Gutierrez A, et al. Elucidation of novel TRAP1-selective inhibitors that regulate mitochondrial processes. Eur J Med Chem. 2023;258:115531. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115531.","journal-title":"Eur J Med Chem"},{"key":"2559_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107747","volume":"221","author":"M Banerjee","year":"2021","unstructured":"Banerjee M, Hatial I, Keegan BM, Blagg BSJ. Assay design and development strategies for finding Hsp90 inhibitors and their role in human diseases. Pharmacol Ther. 2021;221:107747. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107747.","journal-title":"Pharmacol Ther"},{"issue":"1\u20132","key":"2559_CR81","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s10495-019-01577-1","volume":"25","author":"A Mielczarek-Lewandowska","year":"2020","unstructured":"Mielczarek-Lewandowska A, Hartman ML, Czyz M. Inhibitors of HSP90 in melanoma. Apoptosis. 2020;25(1\u20132):12\u201328. https:\/\/doi.org\/10.1007\/s10495-019-01577-1.","journal-title":"Apoptosis"},{"key":"2559_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114516","volume":"238","author":"J Yu","year":"2022","unstructured":"Yu J, Zhang C, Song C. Pan- and isoform-specific inhibition of Hsp90: design strategy and recent advances. Eur J Med Chem. 2022;238:114516. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114516.","journal-title":"Eur J Med Chem"},{"issue":"1\u20132","key":"2559_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543776.2024.2327295","volume":"34","author":"J Liu","year":"2024","unstructured":"Liu J, Shu H, Xia Q, You Q, Wang L. Recent developments of HSP90 inhibitors: an updated patent review (2020-present). Expert Opin Ther Pat. 2024;34(1\u20132):1\u201315. https:\/\/doi.org\/10.1080\/13543776.2024.2327295.","journal-title":"Expert Opin Ther Pat"},{"issue":"16","key":"2559_CR84","doi-asserted-by":"publisher","first-page":"5806","DOI":"10.1016\/j.bmc.2009.07.017","volume":"17","author":"PS Pan","year":"2009","unstructured":"Pan PS, Vasko RC, Lapera SA, Johnson VA, Sellers RP, Lin CC, et al. A comprehensive study of Sansalvamide A derivatives: the structure-activity relationships of 78 derivatives in two pancreatic cancer cell lines. Bioorg Med Chem. 2009;17(16):5806\u201325. https:\/\/doi.org\/10.1016\/j.bmc.2009.07.017.","journal-title":"Bioorg Med Chem"},{"issue":"54","key":"2559_CR85","doi-asserted-by":"publisher","first-page":"39968","DOI":"10.1039\/d4ra07847k","volume":"14","author":"K Herrera-Guzman","year":"2024","unstructured":"Herrera-Guzman K, Jaime-Vasconcelos MA, Torales E, Chacon I, Gavino R, Garcia-Rios E, et al. A practical method for the synthesis of small peptides using DCC and HOBt as activators in H2O-THF while avoiding the use of protecting groups. RSC Adv. 2024;14(54):39968\u201376. https:\/\/doi.org\/10.1039\/d4ra07847k.","journal-title":"RSC Adv"},{"issue":"3","key":"2559_CR86","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1021\/jm070731a","volume":"51","author":"K Otrubova","year":"2008","unstructured":"Otrubova K, Lushington G, Vander Velde D, McGuire KL, McAlpine SR. Comprehensive study of sansalvamide A derivatives and their structure-activity relationships against drug-resistant colon cancer cell lines. J Med Chem. 2008;51(3):530\u201344. https:\/\/doi.org\/10.1021\/jm070731a.","journal-title":"J Med Chem"},{"issue":"18","key":"2559_CR87","doi-asserted-by":"publisher","first-page":"6822","DOI":"10.1016\/j.bmc.2010.07.042","volume":"18","author":"RP Sellers","year":"2010","unstructured":"Sellers RP, Alexander LD, Johnson VA, Lin CC, Savage J, Corral R, et al. Design and synthesis of Hsp90 inhibitors: exploring the SAR of Sansalvamide A derivatives. Bioorg Med Chem. 2010;18(18):6822\u201356. https:\/\/doi.org\/10.1016\/j.bmc.2010.07.042.","journal-title":"Bioorg Med Chem"},{"issue":"10","key":"2559_CR88","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.1021\/acs.molpharmaceut.4c00643","volume":"21","author":"X Wang","year":"2024","unstructured":"Wang X, Han Z, Zhang J, Chen M, Meng W. Development and preclinical evaluation of (18)F-labeled PEGylated Sansalvamide A decapeptide for noninvasive evaluation of Hsp90 status in pancreas cancer. Mol Pharm. 2024;21(10):5238\u201346. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00643.","journal-title":"Mol Pharm"},{"key":"2559_CR89","doi-asserted-by":"publisher","unstructured":"Li Z, Peng T, Yang M, Qiu Y, Ye P, Wang X et al. Dual Functionality of [(64)Cu]Cu-NOTA-San A-Cy7 for Diagnostic Imaging and Surgical Guidance in Hsp90alpha-Positive Tumors. Mol Pharm. 2025.\u00a0https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c00126.","DOI":"10.1021\/acs.molpharmaceut.5c00126"},{"issue":"6","key":"2559_CR90","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1158\/1078-0432.CCR-06-1863","volume":"13","author":"DB Solit","year":"2007","unstructured":"Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res. 2007;13(6):1775\u201382. 10.1158\/1078\u2009\u2013\u20090432.Ccr-06-1863.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2559_CR91","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/cbdd.13486","volume":"93","author":"S Talaei","year":"2019","unstructured":"Talaei S, Mellatyar H, Asadi A, Akbarzadeh A, Sheervalilou R, Zarghami N. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment. Chem Biol Drug Des. 2019;93(5):760\u201386. https:\/\/doi.org\/10.1111\/cbdd.13486.","journal-title":"Chem Biol Drug Des"},{"issue":"6","key":"2559_CR92","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.3892\/or.2020.7563","volume":"43","author":"Y Zuo","year":"2020","unstructured":"Zuo Y, Xu H, Chen Z, Xiong F, Zhang B, Chen K, et al. 17\u2013AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA\u2013MB\u2013231 breast cancer cells. Oncol Rep. 2020;43(6):1928\u201344. https:\/\/doi.org\/10.3892\/or.2020.7563.","journal-title":"Oncol Rep."},{"issue":"2","key":"2559_CR93","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/cas.15204","volume":"113","author":"E Ikebe","year":"2022","unstructured":"Ikebe E, Shimosaki S, Hasegawa H, Iha H, Tsukamoto Y, Wang Y, et al. TAS-116 (pimitespib), a heat shock protein 90 inhibitor, shows efficacy in preclinical models of adult T-cell leukemia. Cancer Sci. 2022;113(2):684\u201396. https:\/\/doi.org\/10.1111\/cas.15204.","journal-title":"Cancer Sci"},{"issue":"24","key":"2559_CR94","doi-asserted-by":"publisher","first-page":"6709","DOI":"10.1158\/1078-0432.CCR-21-1929","volume":"27","author":"A Kawazoe","year":"2021","unstructured":"Kawazoe A, Itahashi K, Yamamoto N, Kotani D, Kuboki Y, Taniguchi H, et al. TAS-116 (Pimitespib), an oral HSP90 Inhibitor, in combination with nivolumab in patients with colorectal cancer and other solid tumors: an Open-Label, Dose-Finding, and expansion phase Ib trial (EPOC1704). Clin Cancer Res. 2021;27(24):6709\u2013. \u2013\u200915.10.1158\/1078\u2009\u2013\u20090432.Ccr-21-1929.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2559_CR95","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2217\/fon-2022-1172","volume":"20","author":"T Doi","year":"2024","unstructured":"Doi T, Yamamoto N, Ohkubo S. Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors. Future Oncol. 2024;20(9):507\u201319. https:\/\/doi.org\/10.2217\/fon-2022-1172.","journal-title":"Future Oncol"},{"issue":"9","key":"2559_CR96","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.annonc.2022.05.518","volume":"33","author":"Y Kurokawa","year":"2022","unstructured":"Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, et al. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2022;33(9):959\u201367. https:\/\/doi.org\/10.1016\/j.annonc.2022.05.518.","journal-title":"Ann Oncol"},{"issue":"6","key":"2559_CR97","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1111\/cas.70058","volume":"116","author":"H Muraoka","year":"2025","unstructured":"Muraoka H, Kazuno H, Hashimoto A, Sootome H, Ohkubo S. Pimitespib, an HSP90 inhibitor, enhances the efficacy of PARP inhibitors in PARP inhibitor-insensitive breast cancer cells. Cancer Sci. 2025;116(6):1745\u201357. https:\/\/doi.org\/10.1111\/cas.70058.","journal-title":"Cancer Sci"},{"issue":"5","key":"2559_CR98","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41416-019-0688-y","volume":"122","author":"Y Saito","year":"2020","unstructured":"Saito Y, Takahashi T, Obata Y, Nishida T, Ohkubo S, Nakagawa F, et al. TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naive and imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2020;122(5):658\u201367. https:\/\/doi.org\/10.1038\/s41416-019-0688-y.","journal-title":"Br J Cancer"},{"issue":"3","key":"2559_CR99","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1158\/1535-7163.Mct-18-0831","volume":"18","author":"A Shimomura","year":"2019","unstructured":"Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, et al. First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors. Mol Cancer Ther. 2019;18(3):531\u201340. https:\/\/doi.org\/10.1158\/1535-7163.Mct-18-0831.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2559_CR100","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1021\/acs.jmedchem.0c01715","volume":"64","author":"C Yoshimura","year":"2021","unstructured":"Yoshimura C, Nagatoishi S, Kuroda D, Kodama Y, Uno T, Kitade M, et al. Thermodynamic dissection of potency and selectivity of cytosolic Hsp90 inhibitors. J Med Chem. 2021;64(5):2669\u201377. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01715.","journal-title":"J Med Chem"},{"key":"2559_CR101","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejca.2019.08.009","volume":"121","author":"T Doi","year":"2019","unstructured":"Doi T, Kurokawa Y, Sawaki A, Komatsu Y, Ozaka M, Takahashi T, et al. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial. Eur J Cancer. 2019;121:29\u201339. https:\/\/doi.org\/10.1016\/j.ejca.2019.08.009.","journal-title":"Eur J Cancer"},{"issue":"12","key":"2559_CR102","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/ijc.34461","volume":"152","author":"R Teranishi","year":"2023","unstructured":"Teranishi R, Takahashi T, Obata Y, Nishida T, Ohkubo S, Kazuno H, et al. Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors. Int J Cancer. 2023;152(12):2580\u201393. https:\/\/doi.org\/10.1002\/ijc.34461.","journal-title":"Int J Cancer."},{"issue":"10","key":"2559_CR103","doi-asserted-by":"publisher","first-page":"9886","DOI":"10.1021\/acs.jmedchem.4c02182","volume":"68","author":"ZW Feng","year":"2025","unstructured":"Feng ZW, Li L, Zhang SD, Wang YJ, Pei JY, Chen NN, et al. Structural optimization of pyrazole compounds as Hsp90 regulators with enhanced antitumor activity. J Med Chem. 2025;68(10):9886\u2013905. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02182.","journal-title":"J Med Chem"},{"issue":"18","key":"2559_CR104","doi-asserted-by":"publisher","first-page":"15968","DOI":"10.1021\/acs.jmedchem.4c00966","volume":"67","author":"X Liang","year":"2024","unstructured":"Liang X, Chen R, Wang C, Wang Y, Zhang J. Targeting HSP90 for cancer therapy: current progress and emerging prospects. J Med Chem. 2024;67(18):15968\u201395. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00966.","journal-title":"J Med Chem"},{"issue":"10","key":"2559_CR105","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.cellsig.2013.06.003","volume":"25","author":"K Wang","year":"2013","unstructured":"Wang K, Lin B. Inhibitor of apoptosis proteins (IAPs) as regulatory factors of hepatic apoptosis. Cell Signal. 2013;25(10):1970\u201380. https:\/\/doi.org\/10.1016\/j.cellsig.2013.06.003.","journal-title":"Cell Signal"},{"issue":"15","key":"2559_CR106","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1200\/jco.2014.59.7328","volume":"33","author":"ML Johnson","year":"2015","unstructured":"Johnson ML, Yu HA, Hart EM, Weitner BB, Rademaker AW, Patel JD, et al. Phase I\/II study of HSP90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2015;33(15):1666\u201373. https:\/\/doi.org\/10.1200\/jco.2014.59.7328.","journal-title":"J Clin Oncol"},{"key":"2559_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108396","volume":"245","author":"J Dernov\u0161ek","year":"2023","unstructured":"Dernov\u0161ek J, Toma\u0161i\u010d T. Following the design path of isoform-selective Hsp90 inhibitors: small differences, great opportunities. Pharmacol Ther. 2023;245:108396. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108396.","journal-title":"Pharmacol Ther"},{"key":"2559_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030624","author":"C Vannas","year":"2022","unstructured":"Vannas C, Andersson L, Dolatabadi S, Ranji P, Lind\u00e9n M, Jonasson E, et al. Different HSP90 inhibitors exert divergent effect on myxoid liposarcoma in vitro and in vivo. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10030624.","journal-title":"Biomedicines"},{"issue":"8","key":"2559_CR109","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1053\/j.gastro.2017.02.039","volume":"152","author":"B Chen","year":"2017","unstructured":"Chen B, Wei W, Ma L, Yang B, Gill RM, Chua MS, et al. Computational discovery of niclosamide ethanolamine, a repurposed drug candidate that reduces growth of hepatocellular carcinoma cells in vitro and in mice by inhibiting cell division cycle 37 signaling. Gastroenterology. 2017;152(8):2022\u201336. https:\/\/doi.org\/10.1053\/j.gastro.2017.02.039.","journal-title":"Gastroenterology"},{"issue":"24","key":"2559_CR110","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.2174\/0109298673313163240829094557","volume":"32","author":"EMH Abbas","year":"2025","unstructured":"Abbas EMH, Sabour R, Alsaiari NA, Medrasi HY, Kassem AF, Farghaly TA. Design, synthesis, and docking of novel tropane hybrids as potent Hsp90 inhibitors with potential anti-breast cancer activity. Curr Med Chem. 2025;32(24):5070\u201384. https:\/\/doi.org\/10.2174\/0109298673313163240829094557.","journal-title":"Curr Med Chem"},{"key":"2559_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.829520","volume":"12","author":"Z Albakova","year":"2022","unstructured":"Albakova Z, Mangasarova Y, Albakov A, Gorenkova L. HSP70 and HSP90 in cancer: cytosolic, endoplasmic reticulum and mitochondrial chaperones of tumorigenesis. Front Oncol. 2022;12:829520. https:\/\/doi.org\/10.3389\/fonc.2022.829520.","journal-title":"Front Oncol"},{"issue":"6","key":"2559_CR112","first-page":"1501","volume":"17","author":"B H\u00e5vik","year":"2007","unstructured":"H\u00e5vik B, Bramham CR. Additive viability-loss following hsp70\/hsc70 double interference and Hsp90 inhibition in two breast cancer cell lines. Oncol Rep. 2007;17(6):1501\u201310.","journal-title":"Oncol Rep"},{"key":"2559_CR113","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-3-44","volume":"3","author":"M Zajac","year":"2010","unstructured":"Zajac M, Gomez G, Benitez J, Mart\u00ednez-Delgado B. Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer. BMC Med Genomics. 2010;3:44. https:\/\/doi.org\/10.1186\/1755-8794-3-44.","journal-title":"BMC Med Genomics"},{"key":"2559_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217691","volume":"622","author":"I Pulido","year":"2025","unstructured":"Pulido I, Luan Q, Pastor-Puente S, Gunder L, Wang Y, Ying C, et al. Chaperone directed heterobifunctional molecules circumvent KRAS(G12C) inhibitor resistance. Cancer Lett. 2025;622:217691. https:\/\/doi.org\/10.1016\/j.canlet.2025.217691.","journal-title":"Cancer Lett"},{"issue":"22","key":"2559_CR115","doi-asserted-by":"publisher","first-page":"12067","DOI":"10.1093\/nar\/gky873","volume":"46","author":"R Avolio","year":"2018","unstructured":"Avolio R, Jarvelin AI, Mohammed S, Agliarulo I, Condelli V, Zoppoli P, et al. Protein Syndesmos is a novel RNA-binding protein that regulates primary cilia formation. Nucleic Acids Res. 2018;46(22):12067\u201386. https:\/\/doi.org\/10.1093\/nar\/gky873.","journal-title":"Nucleic Acids Res."},{"issue":"13","key":"2559_CR116","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1158\/0008-5472.Can-18-0430","volume":"78","author":"A Ruiz-Saenz","year":"2018","unstructured":"Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia N, Moasser MM. HER2 amplification in tumors activates PI3K\/Akt signaling independent of HER3. Cancer Res. 2018;78(13):3645\u201358. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-0430.","journal-title":"Cancer Res"},{"key":"2559_CR117","doi-asserted-by":"publisher","unstructured":"Claus J, Patel G, Autore F, Colomba A, Weitsman G, Soliman TN et al. Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface. Elife. 2018;7.\u00a0https:\/\/doi.org\/10.7554\/eLife.32271.","DOI":"10.7554\/eLife.32271"},{"key":"2559_CR118","doi-asserted-by":"publisher","unstructured":"Niu M, Zhang B, Li L, Su Z, Pu W, Zhao C et al. Targeting HSP90 Inhibits Proliferation and Induces Apoptosis Through AKT1\/ERK Pathway in Lung Cancer. Front Pharmacol. 2021;12:724192.\u00a0https:\/\/doi.org\/10.3389\/fphar.2021.724192.","DOI":"10.3389\/fphar.2021.724192"},{"key":"2559_CR119","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/b978-0-12-397927-8.00015-4","volume":"65","author":"K Jhaveri","year":"2012","unstructured":"Jhaveri K, Modi S. HSP90 inhibitors for cancer therapy and overcoming drug resistance. Adv Pharmacol. 2012;65:471\u2013517. https:\/\/doi.org\/10.1016\/b978-0-12-397927-8.00015-4.","journal-title":"Adv Pharmacol"},{"issue":"5","key":"2559_CR120","doi-asserted-by":"publisher","first-page":"423","DOI":"10.4062\/biomolther.2019.051","volume":"27","author":"S Park","year":"2019","unstructured":"Park S, Park JA, Jeon JH, Lee Y. Traditional and novel mechanisms of heat shock protein 90 (HSP90) inhibition in cancer chemotherapy including HSP90 cleavage. Biomol Ther (Seoul). 2019;27(5):423\u201334. https:\/\/doi.org\/10.4062\/biomolther.2019.051.","journal-title":"Biomol Ther (Seoul)"},{"issue":"11","key":"2559_CR121","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1158\/1541-7786.Mcr-15-0234","volume":"13","author":"LM Butler","year":"2015","unstructured":"Butler LM, Ferraldeschi R, Armstrong HK, Centenera MM, Workman P. Maximizing the therapeutic potential of HSP90 inhibitors. Mol Cancer Res. 2015;13(11):1445\u201351. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-15-0234.","journal-title":"Mol Cancer Res"},{"key":"2559_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1543-z","volume":"15","author":"HJ Kim","year":"2015","unstructured":"Kim HJ, Lee KY, Kim YW, Choi YJ, Lee JE, Choi CM, et al. P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement. BMC Cancer. 2015;15:553. https:\/\/doi.org\/10.1186\/s12885-015-1543-z.","journal-title":"BMC Cancer"},{"issue":"33","key":"2559_CR123","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202310109","volume":"11","author":"S Liu","year":"2024","unstructured":"Liu S, Shen G, Zhou X, Sun L, Yu L, Cao Y, et al. Hsp90 promotes gastric cancer cell metastasis and stemness by regulating the regional distribution of glycolysis-related metabolic enzymes in the cytoplasm. Adv Sci Weinh. 2024;11(33):e2310109. https:\/\/doi.org\/10.1002\/advs.202310109.","journal-title":"Adv Sci Weinh"},{"issue":"1","key":"2559_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32101-w","volume":"13","author":"Y Tan","year":"2022","unstructured":"Tan Y, Li J, Zhao G, Huang KC, Cardenas H, Wang Y, et al. Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells. Nat Commun. 2022;13(1):4554. https:\/\/doi.org\/10.1038\/s41467-022-32101-w.","journal-title":"Nat Commun"},{"issue":"1","key":"2559_CR125","doi-asserted-by":"publisher","first-page":"e13636","DOI":"10.1002\/jcsm.13636","volume":"16","author":"HA Park","year":"2025","unstructured":"Park HA, Sung J, Chang Y, Ryu S, Yoon KJ, Kim HL, et al. Metagenomic analysis identifies sex-related gut microbial functions and bacterial taxa associated with skeletal muscle mass. J Cachexia Sarcopenia Muscle. 2025;16(1):e13636. https:\/\/doi.org\/10.1002\/jcsm.13636.","journal-title":"J Cachexia Sarcopenia Muscle."},{"issue":"6","key":"2559_CR126","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70489","volume":"29","author":"C Subramanian","year":"2025","unstructured":"Subramanian C, Hohenberger KK, Zuo A, Cousineau E, Blagg B, Cohen M. C-terminal Hsp90 inhibitors overcome MEK and BRAF inhibitor resistance in melanoma. J Cell Mol Med. 2025;29(6):e70489. https:\/\/doi.org\/10.1111\/jcmm.70489.","journal-title":"J Cell Mol Med"},{"issue":"8","key":"2559_CR127","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1101\/gr.277755.123","volume":"33","author":"R Avolio","year":"2023","unstructured":"Avolio R, Agliarulo I, Criscuolo D, Sarnataro D, Auriemma M, De Lella S, et al. Cytosolic and mitochondrial translation elongation are coordinated through the molecular chaperone TRAP1 for the synthesis and import of mitochondrial proteins. Genome Res. 2023;33(8):1242\u201357. https:\/\/doi.org\/10.1101\/gr.277755.123.","journal-title":"Genome Res"},{"issue":"7","key":"2559_CR128","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s10147-025-02782-6","volume":"30","author":"MV Shahana","year":"2025","unstructured":"Shahana MV, Choudhary B. HSP90 and the cancer transcriptome: a comprehensive review of inhibitors and mechanistic insights. Int J Clin Oncol. 2025;30(7):1294\u2013308. https:\/\/doi.org\/10.1007\/s10147-025-02782-6.","journal-title":"Int J Clin Oncol"},{"key":"2559_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108782","volume":"163","author":"B Goel","year":"2025","unstructured":"Goel B, Jaiswal S, Tripathi N. Recent advances in HSP90 inhibitors as targeted cancer therapy: chemical scaffolds, isoform selectivity, and clinical progress. Bioorg Chem. 2025;163:108782. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108782.","journal-title":"Bioorg Chem"},{"key":"2559_CR130","doi-asserted-by":"publisher","unstructured":"Kumar A, Rai A, Rangra NK, Singh TG, Ugwuagbo SC, Bhatia R. Recent progress in the development of HSP90 inhibitors: structure-activity relationship and biological evaluation studies. Mol Divers. 2025. https:\/\/doi.org\/10.1007\/s11030-025-11314-3.","DOI":"10.1007\/s11030-025-11314-3"},{"issue":"6","key":"2559_CR131","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.apsb.2020.11.015","volume":"11","author":"MA Serwetnyk","year":"2021","unstructured":"Serwetnyk MA, Blagg BSJ. The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition. Acta Pharm Sin B. 2021;11(6):1446\u201368. https:\/\/doi.org\/10.1016\/j.apsb.2020.11.015.","journal-title":"Acta Pharm Sin B"},{"key":"2559_CR132","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejmech.2019.05.073","volume":"178","author":"S Dutta Gupta","year":"2019","unstructured":"Dutta Gupta S, Bommaka MK, Banerjee A. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer. Eur J Med Chem. 2019;178:48\u201363. https:\/\/doi.org\/10.1016\/j.ejmech.2019.05.073.","journal-title":"Eur J Med Chem"},{"issue":"9","key":"2559_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111734","volume":"41","author":"A Mashaghi","year":"2022","unstructured":"Mashaghi A, Moayed F, Koers EJ, Zheng Y, Till K, Kramer G, et al. Direct observation of Hsp90-induced compaction in a protein chain. Cell Rep. 2022;41(9):111734. https:\/\/doi.org\/10.1016\/j.celrep.2022.111734.","journal-title":"Cell Rep"},{"key":"2559_CR134","doi-asserted-by":"publisher","unstructured":"Montagud A, Beal J, Tobalina L, Traynard P, Subramanian V, Szalai B et al. Patient-specific Boolean models of signalling networks guide personalised treatments. Elife. 2022;11.\u00a0https:\/\/doi.org\/10.7554\/eLife.72626.","DOI":"10.7554\/eLife.72626"},{"issue":"9","key":"2559_CR135","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.18632\/oncotarget.1706","volume":"5","author":"MH Chen","year":"2014","unstructured":"Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, et al. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K\/mTOR dual inhibitor against cholangiocarcinoma. Oncotarget. 2014;5(9):2372\u201389. https:\/\/doi.org\/10.18632\/oncotarget.1706.","journal-title":"Oncotarget"},{"issue":"1","key":"2559_CR136","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-021-02269-4","volume":"19","author":"Y Han","year":"2021","unstructured":"Han Y, Zhang Y, Cui L, Li Z, Feng H, Zhang Y, et al. Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer: in patients with different clinicopathologic characteristics. World J Surg Oncol. 2021;19(1):228. https:\/\/doi.org\/10.1186\/s12957-021-02269-4.","journal-title":"World J Surg Oncol"},{"key":"2559_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.620907","volume":"11","author":"L Yin","year":"2021","unstructured":"Yin L, Yang Y, Zhu W, Xian Y, Han Z, Huang H, et al. Heat shock protein 90 triggers multi-drug resistance of ovarian cancer via AKT\/GSK3\u03b2\/\u03b2-catenin signaling. Front Oncol. 2021;11:620907. https:\/\/doi.org\/10.3389\/fonc.2021.620907.","journal-title":"Front Oncol"},{"key":"2559_CR138","doi-asserted-by":"publisher","unstructured":"Li ZN, Luo Y. HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review). Oncol Rep. 2023;49(1).\u00a0https:\/\/doi.org\/10.3892\/or.2022.8443.","DOI":"10.3892\/or.2022.8443"},{"issue":"8","key":"2559_CR139","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2159-8290.Cd-14-1236","volume":"5","author":"F Skoulidis","year":"2015","unstructured":"Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015;5(8):860\u201377. https:\/\/doi.org\/10.1158\/2159-8290.Cd-14-1236.","journal-title":"Cancer Discov."},{"issue":"10","key":"2559_CR140","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1172\/jci125963","volume":"129","author":"C Pan","year":"2019","unstructured":"Pan C, Chun J, Li D, Boese AC, Li J, Kang J, et al. Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation. J Clin Invest. 2019;129(10):4110\u201323. https:\/\/doi.org\/10.1172\/jci125963.","journal-title":"J Clin Invest"},{"issue":"1","key":"2559_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43486-z","volume":"13","author":"ACL Mortensen","year":"2023","unstructured":"Mortensen ACL, Berglund H, Hariri M, Papalanis E, Malmberg C, Spiegelberg D. Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer. Sci Rep. 2023;13(1):16844. https:\/\/doi.org\/10.1038\/s41598-023-43486-z.","journal-title":"Sci Rep"},{"issue":"43","key":"2559_CR142","doi-asserted-by":"publisher","first-page":"75712","DOI":"10.18632\/oncotarget.20095","volume":"8","author":"X Nan","year":"2017","unstructured":"Nan X, Xie C, Yu X, Liu J. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget. 2017;8(43):75712\u201326. https:\/\/doi.org\/10.18632\/oncotarget.20095.","journal-title":"Oncotarget"},{"issue":"1","key":"2559_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07650-9","volume":"16","author":"Y Sui","year":"2025","unstructured":"Sui Y, Shen Z, Pan R, Ma R, Si R, Feng J, et al. AHSA1-HSP90AA1 complex stabilized IFI6 and TGFB1 promotes mitochondrial stability and EMT in EGFR-mutated lung adenocarcinoma under Osimertinib pressure. Cell Death Dis. 2025;16(1):298. https:\/\/doi.org\/10.1038\/s41419-025-07650-9.","journal-title":"Cell Death Dis"},{"issue":"6","key":"2559_CR144","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.7150\/thno.93236","volume":"14","author":"M Park","year":"2024","unstructured":"Park M, Jung E, Park JM, Park S, Ko D, Seo J, et al. The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer. Theranostics. 2024;14(6):2442\u201363. https:\/\/doi.org\/10.7150\/thno.93236.","journal-title":"Theranostics"},{"issue":"5","key":"2559_CR145","doi-asserted-by":"publisher","first-page":"646","DOI":"10.15252\/embj.201694732","volume":"36","author":"B Diedrich","year":"2017","unstructured":"Diedrich B, Rigbolt KT, R\u00f6ring M, Herr R, Kaeser-Pebernard S, Gretzmeier C, et al. Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition. EMBO J. 2017;36(5):646\u201363. https:\/\/doi.org\/10.15252\/embj.201694732.","journal-title":"EMBO J"},{"issue":"3","key":"2559_CR146","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20177858","volume":"14","author":"A Azimi","year":"2018","unstructured":"Azimi A, Caramuta S, Seashore-Ludlow B, Bostr\u00f6m J, Robinson JL, Edfors F, et al. Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors. Mol Syst Biol. 2018;14(3):e7858. https:\/\/doi.org\/10.15252\/msb.20177858.","journal-title":"Mol Syst Biol"},{"issue":"1","key":"2559_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00449-z","volume":"8","author":"RM Mbofung","year":"2017","unstructured":"Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, et al. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nat Commun. 2017;8(1):451. https:\/\/doi.org\/10.1038\/s41467-017-00449-z.","journal-title":"Nat Commun"},{"key":"2559_CR148","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007625","author":"J Li","year":"2023","unstructured":"Li J, Han X, Sun M, Li W, Yang G, Chen H, et al. Caspase-9 inhibition triggers Hsp90-based chemotherapy-mediated tumor intrinsic innate sensing and enhances antitumor immunity. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-007625.","journal-title":"J Immunother Cancer"},{"key":"2559_CR149","doi-asserted-by":"publisher","unstructured":"Chen Y, Pal S, Li W, Liu F, Yuan S, Hu Q. Engineered platelets as targeted protein degraders and application to breast cancer models. Nat Biotechnol. 2024.\u00a0https:\/\/doi.org\/10.1038\/s41587-024-02494-8.","DOI":"10.1038\/s41587-024-02494-8"},{"issue":"11","key":"2559_CR150","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41580-023-00640-9","volume":"24","author":"G Chiosis","year":"2023","unstructured":"Chiosis G, Digwal CS, Trepel JB, Neckers L. Structural and functional complexity of HSP90 in cellular homeostasis and disease. Nat Rev Mol Cell Biol. 2023;24(11):797\u2013815. https:\/\/doi.org\/10.1038\/s41580-023-00640-9.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"2559_CR151","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.chembiol.2020.10.005","volume":"28","author":"RB Zavareh","year":"2021","unstructured":"Zavareh RB, Spangenberg SH, Woods A, Mart\u00ednez-Pe\u00f1a F, Lairson LL. HSP90 inhibition enhances cancer immunotherapy by modulating the surface expression of multiple immune checkpoint proteins. Cell Chem Biol. 2021;28(2):158-68.e5. https:\/\/doi.org\/10.1016\/j.chembiol.2020.10.005.","journal-title":"Cell Chem Biol"},{"issue":"1","key":"2559_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48597-3","volume":"15","author":"X Xu","year":"2024","unstructured":"Xu X, Xie T, Zhou M, Sun Y, Wang F, Tian Y, et al. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation. Nat Commun. 2024;15(1):4237. https:\/\/doi.org\/10.1038\/s41467-024-48597-3.","journal-title":"Nat Commun"},{"key":"2559_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118014","volume":"186","author":"A Rahimi","year":"2025","unstructured":"Rahimi A, Baghernejadan Z, Hazrati A, Malekpour K, Samimi LN, Najafi A, et al. Combination therapy with immune checkpoint inhibitors in colorectal cancer: challenges, resistance mechanisms, and the role of microbiota. Biomed Pharmacother. 2025;186:118014. https:\/\/doi.org\/10.1016\/j.biopha.2025.118014.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"2559_CR154","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.ccell.2024.03.005","volume":"42","author":"N Niu","year":"2024","unstructured":"Niu N, Shen X, Wang Z, Chen Y, Weng Y, Yu F, et al. Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer. Cancer Cell. 2024;42(5):869-84.e9. https:\/\/doi.org\/10.1016\/j.ccell.2024.03.005.","journal-title":"Cancer Cell."},{"issue":"3","key":"2559_CR155","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-023-02790-x","volume":"30","author":"L Jiang","year":"2024","unstructured":"Jiang L, Qin J, Dai Y, Zhao S, Zhan Q, Cui P, et al. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Nat Med. 2024;30(3):749\u201361. https:\/\/doi.org\/10.1038\/s41591-023-02790-x.","journal-title":"Nat Med"},{"issue":"7","key":"2559_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112807","volume":"42","author":"SJ Backe","year":"2023","unstructured":"Backe SJ, Sager RA, Heritz JA, Wengert LA, Meluni KA, Aran-Guiu X, et al. Activation of autophagy depends on Atg1\/Ulk1-mediated phosphorylation and inhibition of the Hsp90 chaperone machinery. Cell Rep. 2023;42(7):112807. https:\/\/doi.org\/10.1016\/j.celrep.2023.112807.","journal-title":"Cell Rep"},{"issue":"13","key":"2559_CR157","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1016\/j.celrep.2020.03.021","volume":"30","author":"N Santana-Codina","year":"2020","unstructured":"Santana-Codina N, Chandhoke AS, Yu Q, Malachowska B, Kuljanin M, Gikandi A, et al. Defining and Targeting Adaptations to Oncogenic KRAS(G12C) Inhibition Using Quantitative Temporal Proteomics. Cell Rep. 2020;30(13):4584-99.e4. https:\/\/doi.org\/10.1016\/j.celrep.2020.03.021.","journal-title":"Cell Rep."},{"issue":"12","key":"2559_CR158","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/open.202100131","volume":"10","author":"L Pinzi","year":"2021","unstructured":"Pinzi L, Foschi F, Christodoulou MS, Passarella D, Rastelli G. Design and synthesis of Hsp90 inhibitors with B-Raf and PDHK1 multi-target activity. ChemistryOpen. 2021;10(12):1177\u201385. https:\/\/doi.org\/10.1002\/open.202100131.","journal-title":"ChemistryOpen"},{"issue":"5","key":"2559_CR159","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.celrep.2017.10.042","volume":"21","author":"ST Hallett","year":"2017","unstructured":"Hallett ST, Pastok MW, Morgan RML, Wittner A, Blundell K, Felletar I, et al. Differential regulation of G1 CDK complexes by the Hsp90-Cdc37 chaperone system. Cell Rep. 2017;21(5):1386\u201398. https:\/\/doi.org\/10.1016\/j.celrep.2017.10.042.","journal-title":"Cell Rep"},{"issue":"23","key":"2559_CR160","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202402981","volume":"36","author":"Y Liu","year":"2024","unstructured":"Liu Y, Wei Z, Zhang J, Xu Y, Zhou J, Ma Z, et al. Customized enhancement of thermal sensitivity of tumors at different subcutaneous depths by multichannel lanthanide nanocomposites. Adv Mater. 2024;36(23):e2402981. https:\/\/doi.org\/10.1002\/adma.202402981.","journal-title":"Adv Mater"},{"key":"2559_CR161","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201703588","author":"Y Yang","year":"2017","unstructured":"Yang Y, Zhu W, Dong Z, Chao Y, Xu L, Chen M, et al. 1D coordination polymer nanofibers for low-temperature photothermal therapy. Adv Mater. 2017. https:\/\/doi.org\/10.1002\/adma.201703588.","journal-title":"Adv Mater"},{"issue":"2","key":"2559_CR162","doi-asserted-by":"publisher","first-page":"e0045921","DOI":"10.1128\/mcb.00459-21","volume":"42","author":"X Tang","year":"2022","unstructured":"Tang X, Chang C, Mosallaei D, Woodley DT, Sch\u00f6nthal AH, Chen M, et al. Heterogeneous Responses and Isoform Compensation the Dim Therapeutic Window of Hsp90 ATP-Binding Inhibitors in Cancer. Mol Cell Biol. 2022;42(2):e0045921. https:\/\/doi.org\/10.1128\/mcb.00459-21.","journal-title":"Mol Cell Biol."},{"issue":"19","key":"2559_CR163","doi-asserted-by":"publisher","first-page":"10547","DOI":"10.1002\/anie.202015422","volume":"60","author":"SJ Mishra","year":"2021","unstructured":"Mishra SJ, Khandelwal A, Banerjee M, Balch M, Peng S, Davis RE, et al. Selective inhibition of the Hsp90\u03b1 isoform. Angew Chem Int Ed Engl. 2021;60(19):10547\u201351. https:\/\/doi.org\/10.1002\/anie.202015422.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"5","key":"2559_CR164","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","volume":"18","author":"JJ Kovacs","year":"2005","unstructured":"Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005;18(5):601\u20137. https:\/\/doi.org\/10.1016\/j.molcel.2005.04.021.","journal-title":"Mol Cell"},{"key":"2559_CR165","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052538","author":"\u00c1 Marrugal","year":"2021","unstructured":"Marrugal \u00c1, Ferrer I, G\u00f3mez-S\u00e1nchez D, Quintanal-Villalonga \u00c1, Pastor MD, Ojeda L, et al. Identification of predictive biomarkers of response to HSP90 inhibitors in lung adenocarcinoma. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22052538.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2559_CR166","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1021\/jacsau.4c00123","volume":"4","author":"C Xu","year":"2024","unstructured":"Xu C, Zhang X, Zhao L, Verkhivker GM, Bai F. Accurate characterization of binding kinetics and allosteric mechanisms for the HSP90 chaperone inhibitors using AI-augmented integrative biophysical studies. JACS Au. 2024;4(4):1632\u201345. https:\/\/doi.org\/10.1021\/jacsau.4c00123.","journal-title":"JACS Au"},{"key":"2559_CR167","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111957","author":"Y Sakuma","year":"2019","unstructured":"Sakuma Y, Fujii K, Han J, Takahashi RU. Recent advances in liquid biopsy based on circulating tumor DNA. J Clin Med. 2019. https:\/\/doi.org\/10.3390\/jcm8111957.","journal-title":"J Clin Med"},{"issue":"10","key":"2559_CR168","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1021\/ml400082b","volume":"4","author":"SJ Kim","year":"2013","unstructured":"Kim SJ, Ramsey DM, Boyer C, Davis TP, McAlpine SR. Effectively delivering a unique hsp90 inhibitor using star polymers. ACS Med Chem Lett. 2013;4(10):915\u201320. https:\/\/doi.org\/10.1021\/ml400082b.","journal-title":"ACS Med Chem Lett"},{"issue":"23","key":"2559_CR169","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1158\/0008-5472.Can-19-4036","volume":"80","author":"M Smalley","year":"2020","unstructured":"Smalley M, Natarajan SK, Mondal J, Best D, Goldman D, Shanthappa B, et al. Nanoengineered disruption of heat shock protein 90 targets drug-induced resistance and relieves natural killer cell suppression in breast cancer. Cancer Res. 2020;80(23):5355\u201366. https:\/\/doi.org\/10.1158\/0008-5472.Can-19-4036.","journal-title":"Cancer Res"},{"issue":"1","key":"2559_CR170","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90585-w","volume":"11","author":"B Epp-Ducharme","year":"2021","unstructured":"Epp-Ducharme B, Dunne M, Fan L, Evans JC, Ahmed L, Bannigan P, et al. Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro. Sci Rep. 2021;11(1):11103. https:\/\/doi.org\/10.1038\/s41598-021-90585-w.","journal-title":"Sci Rep"},{"issue":"1","key":"2559_CR171","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/ecco-jcc\/jjz113","volume":"14","author":"M Yang","year":"2020","unstructured":"Yang M, Zhang F, Yang C, Wang L, Sung J, Garg P, et al. Oral targeted delivery by nanoparticles enhances efficacy of an Hsp90 inhibitor by reducing systemic exposure in murine models of colitis and colitis-associated cancer. J Crohns Colitis. 2020;14(1):130\u201341. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz113.","journal-title":"J Crohns Colitis"},{"key":"2559_CR172","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102375","author":"TA Debele","year":"2021","unstructured":"Debele TA, Wu PC, Wei YF, Chuang JY, Chang KY, Tsai JH, et al. Transferrin modified GSH sensitive hyaluronic acid derivative micelle to deliver HSP90 inhibitors to enhance the therapeutic efficacy of brain cancers. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13102375.","journal-title":"Cancers (Basel)"},{"key":"2559_CR173","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120817","volume":"273","author":"KS Lim","year":"2021","unstructured":"Lim KS, Lee DY, Han S, Bull DA, Won YW. Targeted delivery of heat shock protein 90 inhibitors prevents growth of HER2-positive tumor. Biomaterials. 2021;273:120817. https:\/\/doi.org\/10.1016\/j.biomaterials.2021.120817.","journal-title":"Biomaterials"},{"issue":"9","key":"2559_CR174","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.7150\/thno.14882","volume":"6","author":"TY Lin","year":"2016","unstructured":"Lin TY, Guo W, Long Q, Ma A, Liu Q, Zhang H, et al. HSP90 inhibitor encapsulated photo-theranostic nanoparticles for synergistic combination cancer therapy. Theranostics. 2016;6(9):1324\u201335. https:\/\/doi.org\/10.7150\/thno.14882.","journal-title":"Theranostics"},{"key":"2559_CR175","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15092252","author":"Y Peng","year":"2023","unstructured":"Peng Y, Jiang H, Li B, Liu Y, Guo B, Gan W. A NIR-activated and mild-temperature-sensitive nanoplatform with an HSP90 inhibitor for combinatory chemotherapy and mild photothermal therapy in cancel cells. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15092252.","journal-title":"Pharmaceutics"},{"issue":"3","key":"2559_CR176","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1021\/acs.molpharmaceut.6b01076","volume":"14","author":"S Sulthana","year":"2017","unstructured":"Sulthana S, Banerjee T, Kallu J, Vuppala SR, Heckert B, Naz S, et al. Combination therapy of NSCLC using Hsp90 inhibitor and doxorubicin carrying functional nanoceria. Mol Pharm. 2017;14(3):875\u201384. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b01076.","journal-title":"Mol Pharm"},{"key":"2559_CR177","doi-asserted-by":"publisher","unstructured":"Felix-Pina P, Franco Molina MA, Zarate Trivino DG, Garcia Coronado PL, Zapata Benavides P, Rodriguez Padilla C. Antitumoral and immunogenic capacity of beta-D-glucose-reduced silver nanoparticles in breast cancer. Int J Mol Sci. 2023;24(10).\u00a0https:\/\/doi.org\/10.3390\/ijms24108485.","DOI":"10.3390\/ijms24108485"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02559-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02559-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02559-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:05:52Z","timestamp":1776164752000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-025-02559-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":177,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2559"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02559-5","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is a comprehensive review of the existing literature and does not contain any original studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not include any individual person\u2019s data in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}